FDA PERSPECTIVE ON AND RESPONSE TO THE RISK OF HEPATITIS-A FROM BLOOD PRODUCTS

被引:3
作者
FRICKE, W [1 ]
机构
[1] US FDA,BETHESDA,MD 20014
关键词
D O I
10.1111/j.1423-0410.1994.tb01292.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The clinical and laboratory data available on hepatitis A virus infections reported in Europe were reviewed by the Blood Pro ducts Advisory Committee of the Food and Drug Administration. The panel's consensus was that the clotting factor concentrates currently available in the United States are safe with respect to viral diseases, hepatitis A transmissions do not appear to be a significant health problem, and there is a paucity of epidemiologic data on hepatitis A in patients with hemophilia in the United States.
引用
收藏
页码:16 / 18
页数:3
相关论文
共 7 条
[1]   VIRAL SAFETY OF CLOTTING FACTOR CONCENTRATES [J].
FRICKE, WA ;
LAMB, MA .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1993, 19 (01) :54-61
[2]   ACUTE HEPATITIS-A IN HEMOPHILIACS [J].
GERRITZEN, A ;
SCHNEWEIS, KE ;
BRACKMANN, HH ;
OLDENBURG, J ;
HANFLAND, P ;
GERLICH, WH ;
CASPARI, G .
LANCET, 1992, 340 (8829) :1231-1232
[3]   INACTIVATION OF VIRUSES IN LABILE BLOOD DERIVATIVES .1. DISRUPTION OF LIPID-ENVELOPED VIRUSES BY TRI( NORMAL-BUTYL)PHOSPHATE DETERGENT COMBINATIONS [J].
HOROWITZ, B ;
WIEBE, ME ;
LIPPIN, A ;
STRYKER, MH .
TRANSFUSION, 1985, 25 (06) :516-522
[4]   OUTBREAK OF HEPATITIS-A AMONG ITALIAN PATIENTS WITH HEMOPHILIA [J].
MANNUCCI, PM .
LANCET, 1992, 339 (8796) :819-819
[6]   ACUTE HEPATITIS-A IN PATIENTS WITH HEMOPHILIA-A [J].
PEERLINCK, K ;
VERMYLEN, J .
LANCET, 1993, 341 (8838) :179-179
[7]  
TEMPERLEY IJ, 1992, LANCET, V340, P1466